LYFAX Performance — AlphaCentric Life Sciences and Healthcare Fund, Class A
Data updated: 2026-08-27
LYFAX returned +17.22% year to date and +54.35% over one year to Jun 2026. Annualised returns are +13.17% over 3 years and +7.60% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $145, against $138 for the category, and to $154 over one year, against $137. Volatility over the past three years was 19.84% a year. In the 12 months to Jun 2026 the fund lost a net $3.5M, and assets reached $46.65M.
LYFAX Growth of $100
What $100 invested in AlphaCentric Life Sciences and Healthcare Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | LYFAX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $154 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $145 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $144 | $121 |
| Since data start (Oct 2019 – Jun 2026) | $238 | $193 |
LYFAX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +17.22% |
| 1 year | +54.35% |
| 3 years (annualised) | +13.17% |
| 5 years (annualised) | +7.60% |
LYFAX Annual Returns
Calendar-year total returns of AlphaCentric Life Sciences and Healthcare Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +17.22% |
| 2025 | +27.89% |
| 2024 | −0.44% |
| 2023 | +6.89% |
| 2022 | −1.06% |
| 2021 | −3.61% |
| 2020 | +54.43% |
| 2019 (Oct–Dec) | +1.30% |
LYFAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.0% | +2.3% | −3.6% | +0.3% | +4.5% | +12.2% | — | — | — | — | — | — |
| 2025 | +5.8% | 0.0% | −2.6% | −3.5% | −4.2% | +2.0% | −1.6% | +6.7% | +5.6% | +10.9% | +8.4% | −1.3% |
| 2024 | −4.0% | +3.2% | +0.1% | −8.4% | +2.8% | +1.1% | +9.9% | +6.2% | −3.0% | +0.2% | −0.3% | −6.8% |
| 2023 | +17.8% | −4.1% | −5.4% | +3.0% | −1.5% | +1.5% | +6.1% | −4.3% | −7.5% | −10.8% | +4.4% | +11.0% |
| 2022 | −3.1% | −0.2% | +6.2% | −13.8% | −4.7% | +7.2% | +6.4% | −0.5% | −7.8% | +5.0% | +5.3% | +1.4% |
| 2021 | +2.9% | +3.2% | −4.2% | +1.7% | −1.2% | +3.2% | −9.7% | +9.1% | −2.5% | −1.9% | −7.6% | +4.8% |
| 2020 | −0.2% | −2.7% | −2.9% | +9.2% | +8.0% | +0.1% | −3.3% | +4.9% | +7.3% | +3.1% | +16.6% | +6.1% |
| 2019 | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | +1.3% |
LYFAX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 19.84%
- 3-year Sharpe ratio: 0.44 (vs 4.5% risk-free rate)
- Best month: +12.24% (Jun 2026)
- Worst month: −10.75% (Oct 2023)
LYFAX Fund Flows
Monthly money in and out of AlphaCentric Life Sciences and Healthcare Fund, from SEC Form N-PORT.
- 12-month net flow: −$3.5M
- 12-month gross sales (incl. reinvestments): $9.7M
- Sales ÷ redemptions: 0.73×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $1.2M | $920K | $256K |
| May 2026 | $439K | $319K | $120K |
| Apr 2026 | $196K | $275K | −$78K |
| Mar 2026 | $606K | $548K | $57K |
| Feb 2026 | $274K | $393K | −$118K |
| Jan 2026 | $3.1M | $580K | $2.5M |
| Dec 2025 | $1.0M | $583K | $443K |
| Nov 2025 | $1.1M | $984K | $134K |
| Oct 2025 | $412K | $4.2M | −$3.8M |
| Sep 2025 | $474K | $901K | −$427K |
| Aug 2025 | $455K | $1.3M | −$802K |
| Jul 2025 | $500K | $2.3M | −$1.8M |
LYFAX Assets Under Management
Net assets of AlphaCentric Life Sciences and Healthcare Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $46.65M |
| 2026-03-31 | $39.32M |
| 2025-12-31 | $37.02M |
| 2025-09-30 | $34.86M |
| 2025-06-30 | $34.42M |
| 2025-03-31 | $44.20M |
| 2024-12-31 | $52.67M |
| 2024-09-30 | $82.91M |
| 2024-06-30 | $82.81M |
| 2024-03-31 | $103.23M |
| 2023-12-31 | $104.23M |
| 2023-09-30 | $103.37M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.